# Efficacy of MND-2119 in Participants With Hypertriglyceridemia

Study · id `cardio:ct-nct03693131` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03693131](<https://clinicaltrials.gov/study/NCT03693131>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT03693131

Browse, organ or system: Metabolism  
Browse, condition area: Risk and prevention; Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 580 participants.

## Technical summary

Registry record NCT03693131. Randomized; quadruple masking; primary purpose treatment. Start 2018-10-27 (actual); primary completion 2019-06-15 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 580 participants (enrolled count; ClinicalTrials.gov record NCT03693131, source copy `cardio:ctgov-nct03693131-2019-08-01`, retrieved 2026-10-31)
- Started: 2018-10-27 (actual) (ClinicalTrials.gov record NCT03693131, source copy `cardio:ctgov-nct03693131-2019-08-01`, retrieved 2026-10-31)
- Primary completion: 2019-06-15 (actual) (ClinicalTrials.gov record NCT03693131, source copy `cardio:ctgov-nct03693131-2019-08-01`, retrieved 2026-10-31)
- Completion: 2019-06-29 (actual) (ClinicalTrials.gov record NCT03693131, source copy `cardio:ctgov-nct03693131-2019-08-01`, retrieved 2026-10-31)
- Countries: Japan (ClinicalTrials.gov record NCT03693131, source copy `cardio:ctgov-nct03693131-2019-08-01`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03693131-2019-08-01`, retrieved 2026-10-31)

## The registry's words

- Brief title: Efficacy of MND-2119 in Participants With Hypertriglyceridemia
- Condition: Hypertriglyceridemia
- Intervention (Drug): Icosapent (MND-2119)
- Intervention (Drug): Icosapent (EPADEL CAPSULES 300)
- Lead sponsor: Mochida Pharmaceutical Company, Ltd.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Dyslipidemia (`cardio:dyslipidemia`)
- Registry condition terms include this condition: High triglycerides (`cardio:hypertriglyceridemia`)
- Registry lists this organization as the lead sponsor: Mochida Pharmaceutical Company, Ltd. (`cardio:org-mochida-pharmaceutical-company-ltd`)

## Provenance

Content hash: 9dbc4af4852200ff9357a85e11cfab8118d482d6de5e00f4c80d31cc7f9c658b
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
